Why Plasmid DNA Quality Sets the Pace for mRNA, Viral Vectors and Cell Therapy
Plasmid DNA is the starting template for mRNA, viral vectors and gene therapies — its yield and purity shape every downstream step.
Read more
The Industry
Why Plasmid DNA Quality Sets the Pace for mRNA, Viral Vectors and Cell Therapy
Plasmid DNA is the starting template for mRNA, viral vectors and gene therapies — its yield and purity shape every downstream step.
Read more
PUPSIT and Annex 1: Why Integrated Aseptic Design Beats Field Assembly
Annex 1 shifts the PUPSIT question from capability to design intent. EMA explains why integrated aseptic systems outperform field-assembled ones.
Read more
Single-Use Bioreactors for CHO Cell Culture: Advantages for High-Density Production and Scale-Up
CHO Cell Culture and Single-Use Bioreactors: Enabling Scalable Biopharmaceutical Manufacturing
Read more
Intensifying Viral Vector Production: Why TFDF Matters for Regional Gene Therapy Manufacturing
How Repligen’s TFDF-based process intensification addresses low yield and complex clarification in AAV and lentivirus manufacturing.
Read more
Continuous Bioprocessing: A Shifting Paradigm for Biologics Manufacturing
Why continuous bioprocessing matters for pharma and biotech manufacturers in Turkey and the region, and how it reshapes biologics production.
Read more
Annex 1 and PUPSIT: Why Integrated Aseptic Design Matters More Than Assembly
With the revised EU GMP Annex 1, PUPSIT capability must be designed into the aseptic system from the start, not added by assembling fittings afterw…
Read more